GSK topped the list, thanks to its June 2021 deal with iTeos for an anti-TIGIT called EOS-448 that totaled more than $2 billion in potential value—over $600 million of which came in upfront cash.

The mechanism has proven challenging, with GSK and iTeos becoming the latest companies to terminate an anti-TIGIT asset. Last month, BeiGene announced it was terminating development of ociperlimab ...

GSK said that the EOS-448/Jemperli combination will start a large randomised trial next year, adding that it now has drug candidates addressing "all three known CD226 checkpoints – TIGIT, CD96 ...

GSK has stopped development of anti-TIGIT antibody belrestotug. The Big Pharma and its partner iTeos Therapeutics took the action after an assessment of the effect on progression-free survival ...

TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

iTeos Therapeutics has said it is evaluating with partner GlaxoSmithKline whether to conduct additional clinical trials of TIGIT drug EOS-448 following the failure of a key trial for Roche's rival ...

GSK pays up big for rights to TIGIT-targeted cancer immunotherapy from Iteos. By Adam Feuerstein June 14, 2021. Reprints. Kirsty Wigglesworth/AP. I teos Therapeutics said Monday that it has sold ...

GlaxoSmithKline has agreed to buy an anti-TIGIT antibody for cancer immunotherapy from iTeos Therapeutics for $625 million upfront and up to $1.45 billion in milestone payments.

GlaxoSmithKline is paying iTeos Therapeutics $625 million up front to share in the development of an antibody that targets the TIGIT protein, a hot target in cancer immunotherapy R&D.

Lung cancer drug from iTeos, GSK shows response, boosting TIGIT as a viable target. Results come amid broader doubts about the approach among some. Manage alerts for this article; ...

GSK and iTeos are the latest companies to scrap a jointly developed anti-TIGIT drug after it failed to demonstrate a meaningful benefit in two Phase II trials. Belrestotug, a human IgG1 antibody ...